AMGN 10-Q Quarterly Report Sept. 30, 2022 | Alphaminr
ALPHAMINR

AMGN 10-Q Quarter ended Sept. 30, 2022

Balance Sheet
Cash Flow
Income Statement
Debt
AMGEN INC
10-Ks and 10-Qs
10-Q
 		Quarter ended March 31, 2024
10-K
 		Fiscal year ended Dec. 31, 2023
10-Q
 		Quarter ended Sept. 30, 2023
10-Q
 		Quarter ended June 30, 2023
10-Q
 		Quarter ended March 31, 2023
10-K
 		Fiscal year ended Dec. 31, 2022
10-Q
 		Quarter ended Sept. 30, 2022
10-Q
 		Quarter ended June 30, 2022
10-Q
 		Quarter ended March 31, 2022
10-K
 		Fiscal year ended Dec. 31, 2021
10-Q
 		Quarter ended Sept. 30, 2021
10-Q
 		Quarter ended June 30, 2021
10-Q
 		Quarter ended March 31, 2021
10-K
 		Fiscal year ended Dec. 31, 2020
10-Q
 		Quarter ended Sept. 30, 2020
10-Q
 		Quarter ended June 30, 2020
10-Q
 		Quarter ended March 31, 2020
10-K
 		Fiscal year ended Dec. 31, 2019
10-Q
 		Quarter ended Sept. 30, 2019
10-Q
 		Quarter ended June 30, 2019
10-Q
 		Quarter ended March 31, 2019
10-K
 		Fiscal year ended Dec. 31, 2018
10-Q
 		Quarter ended Sept. 30, 2018
10-Q
 		Quarter ended June 30, 2018
10-Q
 		Quarter ended March 31, 2018
10-K
 		Fiscal year ended Dec. 31, 2017
10-Q
 		Quarter ended Sept. 30, 2017
10-Q
 		Quarter ended June 30, 2017
10-Q
 		Quarter ended March 31, 2017
10-K
 		Fiscal year ended Dec. 31, 2016
10-Q
 		Quarter ended Sept. 30, 2016
10-Q
 		Quarter ended June 30, 2016
10-Q
 		Quarter ended March 31, 2016
10-K
 		Fiscal year ended Dec. 31, 2015
10-Q
 		Quarter ended Sept. 30, 2015
10-Q
 		Quarter ended June 30, 2015
10-Q
 		Quarter ended March 31, 2015
10-K
 		Fiscal year ended Dec. 31, 2014
10-Q
 		Quarter ended Sept. 30, 2014
10-Q
 		Quarter ended June 30, 2014
10-Q
 		Quarter ended March 31, 2014
10-K
 		Fiscal year ended Dec. 31, 2013
10-Q
 		Quarter ended Sept. 30, 2013
10-Q
 		Quarter ended June 30, 2013
10-Q
 		Quarter ended March 31, 2013
10-K
 		Fiscal year ended Dec. 31, 2012
10-Q
 		Quarter ended Sept. 30, 2012
10-Q
 		Quarter ended June 30, 2012
10-Q
 		Quarter ended March 31, 2012
10-K
 		Fiscal year ended Dec. 31, 2011
10-Q
 		Quarter ended Sept. 30, 2011
10-Q
 		Quarter ended June 30, 2011
10-Q
 		Quarter ended March 31, 2011
10-K
 		Fiscal year ended Dec. 31, 2010
10-Q
 		Quarter ended Sept. 30, 2010
10-Q
 		Quarter ended June 30, 2010
10-Q
 		Quarter ended March 31, 2010
10-K
 		Fiscal year ended Dec. 31, 2009
PROXIES
DEF 14A
 		Filed on April 17, 2024
DEF 14A
 		Filed on April 6, 2023
DEF 14A
 		Filed on April 5, 2022
DEF 14A
 		Filed on April 6, 2021
DEF 14A
 		Filed on April 7, 2020
DEF 14A
 		Filed on April 8, 2019
DEF 14A
 		Filed on April 11, 2018
DEF 14A
 		Filed on April 6, 2017
DEF 14A
 		Filed on April 7, 2016
DEF 14A
 		Filed on April 2, 2015
DEF 14A
 		Filed on April 3, 2014
DEF 14A
 		Filed on April 8, 2013
DEF 14A
 		Filed on April 12, 2012
DEF 14A
 		Filed on April 7, 2011
DEF 14A
 		Filed on March 29, 2010
TABLE OF CONTENTS
Part I Financial InformationItem 1. Financial StatementsItem 2. Management S Discussion and Analysis Of Financial Condition and Results Of OperationsItem 3. Quantitative and Qualitative Disclosures About Market RiskItem 4. Controls and ProceduresPart II Other InformationItem 1. Legal ProceedingsItem 1A. Risk FactorsItem 2. Unregistered Sales Of Equity Securities and Use Of ProceedsItem 6. Exhibits

Exhibits

2.1 Asset Purchase Agreement, dated August 25, 2019, by and between Amgen Inc. and Celgene Corporation.(Filed as an exhibit to Form 8-K on August 26, 2019 and incorporated herein by reference.) 2.2 Amendment No. 1 to the Asset Purchase Agreement, dated October 17, 2019, by and between Amgen Inc. and Celgene Corporation.(Filed as an exhibit to Form 8-K on October 17, 2019 and incorporated herein by reference.) 2.3 Amendment No. 2 to the Asset Purchase Agreement, dated October 17, 2019, by and between Amgen Inc. and Celgene Corporation.(Filed as an exhibit to Form 10-K for the year ended December 31, 2019 on February 12, 2020 and incorporated herein by reference.) 2.4 Letter Agreement, dated November 21, 2019, by and between Amgen Inc. and the parties named therein re: Treatment of Certain Product Inventory in connection with Amgens acquisition of Otezla.(Filed as an exhibit to Form 10-K for the year ended December 31, 2019 on February 12, 2020 and incorporated herein by reference.) 2.5 Irrevocable Guarantee, dated August 25, 2019, by and between Amgen Inc. and Bristol-Myers Squibb Company.(Filed as an exhibit to Form 8-K on August 26, 2019 and incorporated herein by reference.) 2.6 Agreement and Plan of Merger, dated July 27, 2021, by and among Amgen Inc., Teneobio, Inc., Tuxedo Merger Sub, Inc., and Fortis Advisors LLC.(portions of the exhibit have been omitted because they are both (i) not material and (ii) is the type of information that the Company treats as private or confidential)(Filed as an exhibit to Form 10-Q for the quarter ended September 30, 2021 on November 3, 2021 and incorporated herein by reference.) 2.7 Agreement and Plan of Merger, dated as of August 3, 2022, among ChemoCentryx, Inc., Amgen Inc. and Carnation Merger Sub, Inc.(Filed as an exhibit to Form 8-K on August 4, 2022 and incorporated herein by reference.) 3.1 Restated Certificate of Incorporation of Amgen Inc.(As Restated March 6, 2013.) (Filed as an exhibit to Form 10-Q for the quarter ended March 31, 2013 on May 3, 2013 and incorporated herein by reference.) 3.2 Amended and Restated Bylaws of Amgen Inc.(As Amended and Restated February 15, 2016.) (Filed as an exhibit to Form 8-K on February 17, 2016 and incorporated herein by reference.) 4.3 Agreement of Resignation, Appointment and Acceptance dated February 15, 2008.(Filed as an exhibit to Form 10-K for the year ended December 31, 2007 on February 28, 2008 and incorporated herein by reference.) 4.7 Indenture, dated August 4, 2003.(Filed as an exhibit to Form S-3 Registration Statement on August 4, 2003 and incorporated herein by reference.) 4.9 Officers Certificate of Amgen Inc., dated May 30, 2007, including form of the Companys 6.375% Senior Notes due 2037.(Filed as an exhibit to Form 8-K on May 30, 2007 and incorporated herein by reference.) 4.10 Officers Certificate of Amgen Inc., dated May 23, 2008, including form of the Companys 6.90% Senior Notes due 2038.(Filed as exhibit to Form 8-K on May 23, 2008 and incorporated herein by reference.) 4.11 Officers Certificate of Amgen Inc., dated January 16, 2009, including form of the Companys 6.40% Senior Notes due 2039.(Filed as exhibit to Form 8-K on January 16, 2009 and incorporated herein by reference.) 4.12 Officers Certificate of Amgen Inc., dated March 12, 2010, including form of the Companys 5.75% Senior Notes due 2040.(Filed as exhibit to Form 8-K on March 12, 2010 and incorporated herein by reference.) 4.13 Officers Certificate of Amgen Inc., dated September 16, 2010, including form of the Companys 4.95% Senior Notes due 2041.(Filed as an exhibit to Form 8-K on September 17, 2010 and incorporated herein by reference.) 4.14 Officers Certificate of Amgen Inc., dated June 30, 2011, including form of the Companys 5.65% Senior Notes due 2042.(Filed as an exhibit to Form 8-K on June 30, 2011 and incorporated herein by reference.) 4.15 Officers Certificate of Amgen Inc., dated November 10, 2011, including form of the Companys 5.15% Senior Notes due 2041.(Filed as an exhibit to Form 8-K on November 10, 2011 and incorporated herein by reference.) 4.16 Officers Certificate of Amgen Inc., dated December 5, 2011, including form of the Companys 5.50% Senior Notes due 2026.(Filed as an exhibit to Form 8-K on December 5, 2011 and incorporated herein by reference.) 4.17 Officers Certificate of Amgen Inc., dated May 15, 2012, including form of the Companys 5.375% Senior Notes due 2043.(Filed as an exhibit to Form 8-K on May 15, 2012 and incorporated herein by reference.) 4.18 Officers Certificate of Amgen Inc., dated September 13, 2012, including form of the Companys 4.000% Senior Notes due 2029.(Filed as an exhibit to Form 8-K on September 13, 2012 and incorporated herein by reference.) 4.19 Indenture, dated May 22, 2014, between Amgen Inc. and The Bank of New York Mellon Trust Company, N.A., as Trustee.(Filed as an exhibit to Form 8-K on May 22, 2014 and incorporated herein by reference.) 4.20 Officers Certificate of Amgen Inc., dated May 22, 2014, including form of the Companys 3.625% Senior Notes due 2024.(Filed as an exhibit to Form 8-K on May 22, 2014 and incorporated herein by reference.) 4.21 Officers Certificate of Amgen Inc., dated May 1, 2015, including forms of the Companys 3.125% Senior Notes due 2025 and 4.400% Senior Notes due 2045.(Filed as an exhibit on Form 8-K on May 1, 2015 and incorporated herein by reference.) 4.22 Officers Certificate of Amgen Inc., dated as of February 25, 2016, including form of the Companys 2.000% Senior Notes due 2026.(Filed as an exhibit on Form 8-K on February 26, 2016 and incorporated herein by reference.) 4.23 Form of Permanent Global Certificate for the Companys 0.410% bonds due 2023.(Filed as an exhibit on Form 8-K on March 8, 2016 and incorporated herein by reference.) 4.24 Terms of the Bonds for the Companys 0.410% bonds due 2023.(Filed as an exhibit on Form 8-K on March 8, 2016 and incorporated herein by reference.) 4.25 Officers Certificate of Amgen Inc., dated as of June 14, 2016, including forms of the Companys 4.563% Senior Notes due 2048 and 4.663% Senior Notes due 2051.(Filed as an exhibit to Form 8-K on June 14, 2016 and incorporated herein by reference.) 4.26 Officers Certificate of Amgen Inc., dated as of August 19, 2016, including forms of the Companys 2.250% Senior Notes due 2023 and 2.600% Senior Notes due 2026.(Filed as an exhibit to Form 8-K on August 19, 2016 and incorporated herein by reference.) 4.27 Officers Certificate of Amgen Inc., dated as of November 2, 2017, including in the form of the Companys 3.200% Senior Notes due 2027.(Filed as an exhibit to Form 8-K on November 2, 2017 and incorporated herein by reference.) 4.28 Officers Certificate of Amgen Inc., dated as of February 21, 2020, including forms of the Companys 1.900% Senior Notes due 2025, 2.200% Senior Notes due 2027, 2.450% Senior Notes due 2030, 3.150% Senior Notes due 2040 and 3.375% Senior Notes due 2050.(Filed as an exhibit to Form 8-K on February 21, 2020 and incorporated herein by reference.) 4.29 Officers Certificate of Amgen Inc., dated as of May 6, 2020, including form of the Companys 2.300% Senior Notes due 2031.(Filed as an exhibit to Form 8-K on May 6, 2020 and incorporated herein by reference.) 4.30 Officers Certificate of Amgen Inc., dated as of August 17, 2020, including forms of the Companys 2.770% Senior Notes due 2053.(Filed as an exhibit to Form 8-K on August 18, 2020 and incorporated herein by reference.) 4.31 Registration Rights Agreement, dated as of August 17, 2020, by and among Amgen Inc., BofA Securities, Inc. and J.P. Morgan Securities LLC, as lead dealer managers, and BNP Paribas Securities Corp., Deutsche Bank Securities Inc., RBC Capital Markets, LLC, Blaylock Van, LLC and Siebert Williams Shank & Co., LLC, as co-dealer managers.(Filed as an exhibit to Form 8-K on August 18, 2020 and incorporated herein by reference.) 4.32 Officers Certificate of Amgen Inc., dated as of August 9, 2021, including forms of the Companys 1.650% Senior Notes due 2028, 2.000% Senior Notes due 2032, 2.800% Senior Notes due 2041 and 3.000% Senior Notes due 2052. (Filed as an exhibit to Form 8-K on August 9, 2021 and incorporated herein by reference.) 4.33 Officers Certificate of Amgen Inc., dated as of February 22, 2022, including forms of the Companys 3.000% Senior Notes due 2029, 3.350% Senior Notes due 2032, 4.200% Senior Notes due 2052 and 4.400% Senior Notes due 2062. (Filed as an exhibit to Form 8-K on February 22, 2022 and incorporated herein by reference.) 4.34 Officers Certificate of Amgen Inc., dated as of August 18, 2022, including forms of the Companys 4.050% Senior Notes due 2029, 4.200% Senior Notes due 2033 and 4.875% Senior Notes due 2053.(Filed as an exhibit to Form 8-K on August 18, 2022 and incorporated herein by reference.) 10.2+ First Amendment to Amgen Inc. Amended and Restated 2009 Equity Incentive Plan, effective March 4, 2015.(Filed as an exhibit to Form 10-Q for the quarter ended March 31, 2015 on April 27, 2015 and incorporated herein by reference.) 10.3+ Second Amendment to Amgen Inc. Amended and Restated 2009 Equity Incentive Plan, effective March 2, 2016.(Filed as an exhibit to Form 10-Q for the quarter ended March 31, 2016 on May 2, 2016 and incorporated herein by reference.) 10.4+ Form of Grant of Stock Option Agreement for the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan. (As Amended and Restated on December 2, 2021.)(Filed as an exhibit to Form 10-K for the year ended December 31, 2021 on February 16, 2022 and incorporated herein by reference.) 10.5+ Form of Restricted Stock Unit Agreement for the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan. (As Amended and Restated on December 2, 2021.)(Filed as an exhibit to Form 10-K for the year ended December 31, 2021 on February 16, 2022 and incorporated herein by reference.) 10.6+ Amgen Inc. 2009 Performance Award Program. (As Amended on December 12, 2017.)(Filed as an exhibit to Form 10-K for the year ended December 31, 2017 on February 13, 2018 and incorporated herein by reference.) 10.7+ Form of Performance Unit Agreement for the Amgen Inc. 2009 Performance Award Program. (As Amended and Restated on December 2, 2021.)(Filed as an exhibit to Form 10-K for the year ended December 31, 2021 on February 16, 2022 and incorporated herein by reference.) 10.8+ Amgen Inc. 2009 Director Equity Incentive Program. (As Amended and Restated on October 21, 2020.)(Filed as an exhibit to Form 10-K for the year ended December 31, 2020 on February 9, 2021 and incorporated herein by reference.) 10.9+ Form of Grant of Non-Qualified Stock Option Agreement for the Amgen Inc. 2009 Director Equity Incentive Program.(Filed as an exhibit to Form 8-K on May 8, 2009 and incorporated herein by reference.) 10.10+ Form of Restricted Stock Unit Agreement for the Amgen Inc. 2009 Director Equity Incentive Program. (As Amended on December 11, 2019.)(Filed as an exhibit to Form 10-K for the year ended December 31, 2019 on February 12, 2020 and incorporated herein by reference.) 10.11+ Form of Cash-Settled Restricted Stock Unit Agreement for the Amgen 2009 Director Equity Incentive Program. (As Amended on December 11, 2019.)(Filed as an exhibit to Form 10-K for the year ended December 31, 2019 on February 12, 2020 and incorporated herein by reference.) 10.12+ Amgen Inc. Supplemental Retirement Plan. (As Amended and Restated effective October 16, 2013.)(Filed as an exhibit to Form 10-K for the year ended December 31, 2013 on February 24, 2014 and incorporated herein by reference.) 10.13+ First Amendment to the Amgen Inc. Supplemental Retirement Plan, effective October 14, 2016.(Filed as an exhibit to Form 10-Q for the quarter ended September 30, 2016 on October 28, 2016 and incorporated herein by reference.) 10.14+ Second Amendment to the Amgen Inc. Supplemental Retirement Plan, effective October 23, 2019).(Filed as an exhibit to Form 10-K for the year ended December 31, 2019 on February 12, 2020 and incorporated herein by reference.) 10.15+ Third Amendment to the Amgen Inc. Supplemental Retirement Plan, effective October 20, 2021.(Filed as an exhibit to Form 10-K for the year ended December 31, 2021 on February 16, 2022 and incorporated herein by reference.) 10.16+ Amended and Restated Amgen Change of Control Severance Plan. (As Amended and Restated effective December 9, 2010 and subsequently amended effective March 2, 2011.)(Filed as an exhibit to Form 10-Q for the quarter ended March 31, 2011 on May 10, 2011 and incorporated herein by reference.) 10.17+ Amgen Inc. Executive Incentive Plan.(As Amended and Restated effective January1, 2022.) (Filed as an exhibit to Form 10-Q for the quarter ended March 31, 2022 on April 28, 2022 and incorporated herein by reference.) 10.18+ Amgen Nonqualified Deferred Compensation Plan. (As Amended and Restated effective October 16, 2013.)(Filed as an exhibit to Form 10-K for the year ended December 31, 2013 on February 24, 2014 and incorporated herein by reference.) 10.19+ First Amendment to the Amgen Nonqualified Deferred Compensation Plan, effective October 14, 2016.(Filed as an exhibit to Form 10-Q for the quarter ended September 30, 2016 on October 28, 2016 and incorporated herein by reference.) 10.20+ Second Amendment to the Amgen Nonqualified Deferred Compensation Plan, effective January 1, 2020.(Filed as an exhibit to Form 10-K for the year ended December 31, 2019 on February 12, 2020 and incorporated herein by reference.) 10.21+ Third Amendment to the Amgen Nonqualified Deferred Compensation Plan, effective January 1, 2022.(Filed as an exhibit to Form 10-K for the year ended December 31, 2021 on February 16, 2022 and incorporated herein by reference.) 10.22+ Agreement between Amgen Inc. and Peter Griffith, dated October 18, 2019.(Filed as an exhibit to Form 10-Q for the quarter ended March 31, 2020 on May 1, 2020 and incorporated herein by reference.) 10.23+ Aircraft Time Sharing Agreement, dated December 3, 2021, by and between Amgen Inc. and Robert A. Bradway.(Filed as an exhibit to Form 10-K for the year ended December 31, 2021 on February 16, 2022 and incorporated herein by reference.) 10.24 Second Amended and Restated Credit Agreement, dated December 12, 2019, among Amgen Inc., the Banks therein named, Citibank, N.A., as administrative agent, and JPMorgan Chase Bank, N.A., as syndication agent.(Filed as an exhibit to Form 8-K on December 12, 2019 and incorporated herein by reference.) 10.25 Collaboration and License Agreement between Amgen Inc. and Celltech R&D Limited dated May 10, 2002 (portions of the exhibit have been omitted pursuant to a request for confidential treatment) and Amendment No. 1, effective June 9, 2003, to Collaboration and License Agreement between Amgen Inc. and Celltech R&D Limited (portions of the exhibit have been omitted pursuant to a request for confidential treatment).(Filed as an exhibit to Form 10-K/A for the year ended December 31, 2012 on July 31, 2013 and incorporated herein by reference.) 10.26 Amendment No. 2 to Collaboration and License Agreement, effective November 14, 2016, between Amgen Inc. and Celltech R&D Limited (portions of the exhibit have been omitted pursuant to a request for confidential treatment).(Filed as an exhibit to Form 10-K for the year ended December 31, 2016 on February 14, 2017 and incorporated herein by reference.) 10.27 Letter Agreement, dated June 25, 2019, by and between Amgen Inc. and UCB Celltech (portions of the exhibit have been omitted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed).(Filed as an exhibit to Form 10-Q for the quarter ended June 30, 2019 on July 31, 2019 and incorporated herein by reference.) 10.28 Collaboration Agreement, dated April 22, 1994, by and between Bayer Corporation (formerly Miles, Inc.) and Onyx Pharmaceuticals, Inc.(Filed as an exhibit to Form 10-Q for the quarter ended March 31, 2011 by Onyx Pharmaceuticals, Inc. on May 10, 2011 and incorporated herein by reference.) 10.29 Amendment to Collaboration Agreement, dated April 24, 1996, by and between Bayer Corporation and Onyx Pharmaceuticals, Inc.(Filed as an exhibit to Form 10-Q for the quarter ended March 31, 2006 by Onyx Pharmaceuticals, Inc. on May 10, 2006 and incorporated herein by reference.) 10.30 Amendment to Collaboration Agreement, dated February 1, 1999, by and between Bayer Corporation and Onyx Pharmaceuticals, Inc.(Filed as an exhibit to Form 10-Q for the quarter ended March 31, 2006 by Onyx Pharmaceuticals, Inc. on May 10, 2006 and incorporated herein by reference.) 10.31 Settlement Agreement and Release, dated October 11, 2011, by and between Bayer Corporation, Bayer AG, Bayer HealthCare LLC and Bayer Pharma AG and Onyx Pharmaceuticals, Inc.(Filed as an exhibit to Form 10-K for the year ended December 31, 2011 by Onyx Pharmaceuticals, Inc. on February 27, 2012 and incorporated herein by reference.) 10.32 Fourth Amendment to Collaboration Agreement, dated October 11, 2011, by and between Bayer Corporation and Onyx Pharmaceuticals, Inc.(Filed as an exhibit to Form 10-K for the year ended December 31, 2011 by Onyx Pharmaceuticals, Inc. on February 27, 2012 and incorporated herein by reference.) 10.33 Side Letter Regarding Collaboration Agreement, dated May 29, 2015, by and between Bayer HealthCare LLC and Onyx Pharmaceuticals, Inc.(Filed as an exhibit to Form 10-Q for the quarter ended June 30, 2015 on August 5, 2015 and incorporated herein by reference.) 10.34 Side Letter Regarding Collaboration Agreement and Stivarga Agreement, dated February 13, 2020, by and between Onyx Pharmaceuticals, Inc. and Bayer HealthCare LLC.(Filed as an exhibit to Form 10-Q for the quarter ended March 31, 2020 on May 1, 2020 and incorporated herein by reference.) 10.35 Sourcing and Supply Agreement, dated January 6, 2017, by and between Amgen USA Inc., a wholly owned subsidiary of Amgen Inc., and DaVita Inc.(portions of the exhibit have been omitted pursuant to a request for confidential treatment). (Filed as an exhibit to Form 10-Q for the quarter ended March 31, 2017 on April 27, 2017 and incorporated herein by reference.) 10.36* Amendment No. 1 to Sourcing and Supply Agreement, dated July 14, 2022, by and between Amgen USA Inc., a wholly owned subsidiary of Amgen Inc., and DaVita Inc. (portions of the exhibit have been omitted because they are both (i) not material and (ii) is the type of information that the Company treats as private or confidential.) 10.37 Exclusive License and Collaboration Agreement, dated August 28, 2015, by and between Amgen Inc. and Novartis Pharma AG(portions of the exhibit have been omitted pursuant to a request for confidential treatment). (Filed as an exhibit to Form 10-Q for the quarter ended June 30, 2017 on July 26, 2017 and incorporated herein by reference.) 10.38 Amendment No. 1 to the Exclusive License and Collaboration Agreement, dated April 21, 2017, by and between Amgen Inc. and Novartis Pharma AG(portions of the exhibit have been omitted pursuant to a request for confidential treatment). (Filed as an exhibit to Form 10-Q for the quarter ended June 30, 2017 on July 26, 2017 and incorporated herein by reference.) 10.39 Amendment No. 2 to the Exclusive License and Collaboration Agreement, dated April 21, 2017, by and between Amgen Inc. and Novartis Pharma AG(portions of the exhibit have been omitted pursuant to a request for confidential treatment). (Filed as an exhibit to Form 10-Q for the quarter ended June 30, 2017 on July 26, 2017 and incorporated herein by reference.) 10.40 Amendment No. 3 to the Exclusive License and Collaboration Agreement, dated January 31, 2022, by and between Amgen Inc. and Novartis Pharma AG(portions of the exhibit have been omitted because they are both (i) not material and (ii) is the type of information that the Company treats as private or confidential). (Filed as an exhibit to the Companys Current Report on Form 8-K on January 31, 2022 and incorporated herein by reference.) 10.41 Collaboration Agreement, dated October 31, 2019, by and between Amgen Inc. and BeiGene Switzerland GmbH, a wholly-owned subsidiary of BeiGene, Ltd.(portions of the exhibit have been omitted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed). (Filed as an exhibit to Form 10-K for the year ended December 31, 2019 on February 12, 2020 and incorporated herein by reference.) 10.42 First Amendment to Collaboration Agreement, dated April 20, 2022, by and between Amgen Inc. and BeiGene Switzerland GmbH, and BeiGene, Ltd.(portions of the exhibit have been omitted because they are both (i) not material and (ii) is the type of information that the Company treats as private or confidential.) (Filed as an exhibit to Form 10-Q for the quarter ended June 30, 2022 on August 5, 2022 and incorporated herein by reference.) 10.43 Guarantee, dated as of October 31, 2019, made by and among BeiGene, Ltd. and Amgen Inc.(Filed as an exhibit to Form 10-K for the year ended December 31, 2019 on February 12, 2020 and incorporated herein by reference.) 10.44 Share Purchase Agreement, dated October 31, 2019, by and between Amgen Inc. and BeiGene, Ltd.(portions of the exhibit have been omitted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed). (Filed as an exhibit to Schedule 13D on January 8, 2020 and incorporated herein by reference.) 10.45 Amendment No. 1 to Share Purchase Agreement, dated December 6, 2019, by and among BeiGene, Ltd. and Amgen Inc.(Filed as an exhibit to Schedule 13D on January 8, 2020 and incorporated herein by reference.) 10.46 Restated Amendment No. 2 to Share Purchase Agreement, dated September 24, 2020, by and among BeiGene, Ltd. and Amgen Inc.(Filed as an exhibit to Form 10-Q for the quarter ended September 30, 2020 on October 29, 2020 and incorporated herein by reference.) 10.47 Collaboration Agreement dated March 30, 2012 by and between Amgen Inc. and AstraZeneca Collaboration Ventures, LLC, a wholly owned subsidiary of AstraZeneca Pharmaceuticals LP(portions of the exhibit have been omitted because they are both (i) not material and (ii) is the type of information that the Company treats as private or confidential.) (Filed as an exhibit to Form 10-Q for the quarter ended June 30, 2022 on August 5, 2022 and incorporated herein by reference.) 10.48 Amendment No. 1 to the Collaboration Agreement, dated October 1, 2014, by and among Amgen Inc., AstraZeneca Collaboration Ventures, LLC and AstraZeneca Pharmaceuticals LP(portions of the exhibit have been omitted because they are both (i) not material and (ii) is the type of information that the Company treats as private or confidential.) (Filed as an exhibit to Form 10-Q for the quarter ended June 30, 2022 on August 5, 2022 and incorporated herein by reference.) 10.49 Amendment Nos. 2 through 6 to the March 30, 2012 Collaboration Agreement between Amgen Inc. and AstraZeneca Collaboration Ventures, LLC, dated May 2 and 27 and October 2, 2016, January 31, 2018, and May 15, 2020, respectively(portions of the exhibit have been omitted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed.) (Filed as an exhibit to Form 10-Q for the quarter ended June 30, 2020 on July 29, 2020 and incorporated herein by reference.) 10.50 Amendment No. 7 to the Collaboration Agreement, dated December 17, 2020, by and between Amgen Inc. and AstraZeneca Collaboration Ventures, LLC(portions of the exhibit have been omitted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed.) (Filed as an exhibit to Form 10-K for the year ended December 31, 2020 on February 9, 2021 and incorporated herein by reference.) 10.51 Amendment No. 8 to the Collaboration Agreement, dated November 19, 2021, by and between Amgen Inc. and AstraZeneca Collaboration Ventures, LLC(portions of the exhibit have been omitted because they are both (i) not material and (ii) is the type of information that the Company treats as private or confidential.)(Filed as an exhibit to Form 10-K for the year ended December 31, 2021 on February 16, 2022 and incorporated herein by reference.) 10.52 License and Collaboration Agreement, dated June 1, 2021, by and between Amgen Inc. and Kyowa Kirin Co., Ltd.(portions of the exhibit have been omitted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed). (Filed as an exhibit to Form 10-Q for the quarter ended June 30, 2021 on August 4, 2021 and incorporated herein by reference.) 10.53 Form of ASR Agreement.(Filed as an exhibit to Form 8-K on February 24, 2022 and incorporated herein byreference.) 31* Rule 13a-14(a) Certifications. 32** Section 1350 Certifications.